Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

• Published in: European neuropsychopharmacology Vol. 26; no. 4; pp. 756 - 766
• Main Authors: Pokorny, Thomas, Preller, Katrin H., Kraehenmann, Rainer, Vollenweider, Franz X.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2016
• Subjects: 5-HT1A receptor; 5-HT2A receptor; Behavior Rating Scale; Buspirone; Buspirone - pharmacology; Consciousness Disorders - chemically induced; Consciousness Disorders - psychology; Double-Blind Method; Ergotamine; Ergotamine - pharmacology; Female; Hallucinogens - pharmacology; Healthy Volunteers - psychology; Humans; Internal Medicine; Male; Psilocybin; Psilocybin - antagonists & inhibitors; Psilocybin - pharmacology; Psychiatry; Serotonin Receptor Agonists - pharmacology; Visual hallucinations; Young Adult; Ergotamine; 5-HT2A receptor; Buspirone; Psilocybin; Visual hallucinations; 5-HT1A receptor

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT...